Taylor, Nathan Gary Arthur (2016) Development of a robust virus-based assay for determination of 50% effective concentration and analysis of drug resistance in the hepatitis C virus. Masters thesis, Memorial University of Newfoundland.
[English]
PDF
- Accepted Version
Available under License - The author retains copyright ownership and moral rights in this thesis. Neither the thesis nor substantial extracts from it may be printed or otherwise reproduced without the author's permission. Download (642kB) |
Abstract
Hepatitis C virus affects 170 million people worldwide and until recently, therapeutic options have been limited. Novel and effective protease inhibitors (PI) became available in the clinic in 2011, and a plethora of new compounds and classes of compounds have been developed since. Due to the HCV polymerase lacking a proofreading mechanism, resistance to these compounds arises and decreases the success rate of treatment. Classically, drug resistance has been studied in the context of a system that does not recapitulate the entire HCV life cycle. With an established cell culture model of HCV infection in our lab we developed a novel assay for characterization of mutations conferring resistance to direct-acting antiviral compounds. We designed, improved and validated the assay with compounds stemming from different chemical classes including an NS3/4A inhibitor, NS5A inhibitors and NS5B inhibitors. Herein we present the development and implementation of the assay. With this assay in hand a more comprehensive understanding of HCV drug resistance can be realized and used as a tool for future drug development, both in HCV and in other related viruses.
Item Type: | Thesis (Masters) |
---|---|
URI: | http://research.library.mun.ca/id/eprint/12375 |
Item ID: | 12375 |
Additional Information: | Includes bibliographical references (pages 52-65). |
Keywords: | Hepatitis C Virus, Drug Resistance, EC50, Protease Inhibitors |
Department(s): | Medicine, Faculty of |
Date: | October 2016 |
Date Type: | Submission |
Library of Congress Subject Heading: | Hepatitis C virus; Drug resistance |
Medical Subject Heading: | Hepacivirus; Drug Resistance |
Actions (login required)
View Item |